Celgene Corporation (CELG) Announces Appointment of Jennifer Dudinak to Senior Vice President of Global Regulatory Affairs


Celgene Corporation Announces Appointment of Jennifer Dudinak to Senior Vice President of Global Regulatory Affairs

Celgene Corporation (CELG) today announced the appointment of Jennifer Dudinak, Pharm.D., as Senior Vice President, Global Regulatory Affairs, reporting to Jay Backstrom, M.D., Chief Medical Officer, effective April 30, 2018. Jennifer will be responsible for regulatory strategy and execution across Celgene’s portfolio and will serve on the company’s Executive Committee.

“Jennifer possesses deep regulatory expertise and has a proven record of leading highly-effective cross-functional teams,” said Jay Backstrom, M.D., Chief Medical Officer of Celgene Corporation. “Jennifer will lead the regulatory strategy at all stages of our pipeline, which is essential to accelerate and expand our portfolio.”

“Strengthening our Regulatory Affairs team is critical to our future success and is a top corporate objective at this stage of Celgene’s growth,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene Corporation. “Jennifer is an outstanding addition to Jay’s global leadership team and the Executive Committee.”

Jennifer has more than 20 years of regulatory experience, integrating regulatory strategy into drug development and precision medicine across multiple therapeutic areas. She joins Celgene from GlaxoSmithKline (GSK), where she was Vice President and Head of Regulatory Affairs for the Pharma Therapeutic Team. Also at GSK, she served as Vice President of Global Regulatory Affairs for Oncology, in addition to providing regulatory leadership on a number of innovation and operational excellence initiatives. Prior to joining GSK, Jennifer served as Global Head of Regulatory Affairs for Inflammation, Virology and Ophthalmology and Therapeutic Group Head of Regulatory Affairs for Oncology at Genentech/Hoffman-La Roche, where she completed her Pharmacy Post-Doctoral Fellowship. Jennifer received her Doctor of Pharmacy and Bachelor of Science in Pharmacy from Rutgers University.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

Forward-Looking Statement

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180430005395/en/


Please enter your comment!
Please enter your name here